Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Clearside Biomedical (NASDAQ: CLSD)

By Ryan Adsit

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPTResearch Report) and Clearside Biomedical (CLSDResearch Report).

Sarepta Therapeutics (SRPT)

In a report released today, Hartaj Singh from Oppenheimer maintained a Hold rating on Sarepta Therapeutics. The company’s shares closed yesterday at $114.50.

Singh commented:

“Sarepta (SRPT) reported 1Q19 financial results and provided a corporate update on its progress for the quarter. The quarterly results were relatively benign and effectively in line with our estimates (Exondys 51 sales of $87M). On the conference call, we heard added color on competitive pressures in DMD gene therapy (PFE), which could remain on investor minds until the initial readout in June. We continue to believe more work lay ahead in gene therapy, despite Sarepta’s early results, and look forward to management’s execution on its manufacturing initiatives in 2019. As we remain focused on SRPT’s execution across its gene therapy pipeline, as well as regulatory clarity on the registration path forward, we stay neutral.”

According to, Singh is a 2-star analyst with an average return of 0.7% and a 40.2% success rate. Singh covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Strongbridge Biopharma Plc, and Catabasis Pharmaceuticals.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $207.

See today’s analyst top recommended stocks >>

Clearside Biomedical (CLSD)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical today and set a price target of $4. The company’s shares closed yesterday at $1.21, close to its 52-week low of $0.99.

According to, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.5% and a 35.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.

Currently, the analyst consensus on Clearside Biomedical is a Moderate Buy with an average price target of $4.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.